The first few months of 2026 set a productive tone for Curasight. Following early positive data from the phase I trial in aggressive brain cancer, the company has fortified its board of directors by adding important industry players and also strengthened its financial base. BioStock contacted CEO Ulrich Krasilnikoff for a comment.
Read the full interview at biostock.se:
Curasight advances uTREAT through first-in-human development as key clinical data approaches
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/